{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:18:20Z","timestamp":1775056700008,"version":"3.50.1"},"reference-count":14,"publisher":"The Journal of Rheumatology","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2018,10,18]]},"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective.<\/jats:title>\n                    <jats:p>To compare safety and efficacy outcomes between the cyclophosphamide (CYC) arms of Scleroderma Lung Study (SLS) I and II.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>Participants enrolled in the CYC arms of SLS I (n = 79) and II (n = 69) were included. SLS I and II randomized participants to oral CYC for 1 year and followed patients for an additional year off therapy (in SLS II, patients received placebo in Year 2). Eligibility criteria for SLS I and II were nearly identical. Outcomes included the forced vital capacity (FVC%)-predicted and DLCO%-predicted (measured every 3 mos) and quantitative radiographic extent of interstitial lung disease (measured at 1 and 2 yrs for SLS I and SLS II, respectively). Joint models were created to evaluate the treatment effect on the course of the FVC\/DLCO over 2 years while controlling for baseline disease severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>SLS I and II CYC participants had similar baseline characteristics. After adjusting for baseline disease severity, there was no difference in the course of the FVC%-predicted (p = 0.535) nor the DLCO%-predicted (p = 0.172) between the SLS I and II CYC arms. In both groups, treatment with CYC led to a significant improvement in the FVC%-predicted from 3 to 12 months, but no significant improvement beyond this point. Treatment with CYC had no effect on the DLCO for either group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion.<\/jats:title>\n                    <jats:p>Treatment with 1 year of oral CYC led to similar improvements in lung function in both SLS I and II, although the effects were not sustained following cessation of CYC. These results suggest that increasing the duration of ILD therapy may improve outcomes for patients with systemic sclerosis\u2013ILD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.180441","type":"journal-article","created":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T12:19:33Z","timestamp":1550233173000},"page":"1316-1325","source":"Crossref","is-referenced-by-count":30,"title":["Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II"],"prefix":"10.3899","volume":"46","author":[{"given":"Elizabeth R.","family":"Volkmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald P.","family":"Tashkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myung","family":"Sim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Clements","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Maria","family":"Hoffmann-Vold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel E.","family":"Furst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Goldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Elashoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2019,2,15]]},"reference":[{"key":"2026040106401360000_46.10.1316.1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker269"},{"key":"2026040106401360000_46.10.1316.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.114264"},{"key":"2026040106401360000_46.10.1316.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055120"},{"key":"2026040106401360000_46.10.1316.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.22204"},{"key":"2026040106401360000_46.10.1316.5","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2026040106401360000_46.10.1316.6","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200702-326OC"},{"key":"2026040106401360000_46.10.1316.7","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4507"},{"key":"2026040106401360000_46.10.1316.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1541-0420.2007.00952.x"},{"key":"2026040106401360000_46.10.1316.9","doi-asserted-by":"publisher","DOI":"10.1378\/chest.85.6.751"},{"key":"2026040106401360000_46.10.1316.10","doi-asserted-by":"publisher","DOI":"10.1081\/COPD-120030829"},{"key":"2026040106401360000_46.10.1316.11","first-page":"1892","article-title":"Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies","volume":"20","author":"Clements","year":"1993","journal-title":"J Rheumatol"},{"key":"2026040106401360000_46.10.1316.12","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-0108"},{"key":"2026040106401360000_46.10.1316.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2008.03.011"},{"key":"2026040106401360000_46.10.1316.14","unstructured":"Clements PJ Medsger TA Jr Feghali CA . Cutaneous involvement in systemic sclerosis. In: Clements PJ Furst DE , editors. Systemic sclerosis, 2nd ed. Philadelphia: Lippincott Williams and Wilkins; 2004:129\u201350."}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.180441","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T13:41:14Z","timestamp":1775050874000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.180441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,15]]},"references-count":14,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10,1]]},"published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.3899\/jrheum.180441"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.180441","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,15]]}}}